CHRISTOPHER G. TWITTY, Ph.D.
CHIEF SCIENTIFIC OFFICER
Dr. Twitty brings over 20 years of experience in tumor immunology and cancer immunotherapy. He oversees OncoSec’s R&D program and was responsible for the development of clinical immune monitoring and biomarker program.
SANDRA AUNG, Ph.D.
SENIOR VICE PRESIDENT, CHIEF CLINICAL DEVELOPMENT OFFICER
Dr. Aung has over 20 years of experience in the pharmaceutical and biotechnology industry, and has led teams and projects in companies of different sizes.
ROBERT W. ASHWORTH, Ph.D.
SENIOR VICE PRESIDENT, REGULATORY QUALITY AND CMC
With more than 35 years of experience in the pharmaceutical industry, Dr. Ashworth is well-versed in drug development and global regulatory strategies and has made significant contributions to the FDA approval of 12 new drugs.
ROBERT J. DELAVERSANO, C.P.A.
VICE PRESIDENT, FINANCE
Mr. DelAversano is a certified public account and has over fifteen years of experience in accounting including thirteen years in public accounting.
BRIDGET O'KEEFFE, Ph.D.
VICE PRESIDENT, CLINICAL DEVELOPMENT
Dr. O’Keeffe is a biotech industry veteran who brings more than 15 years of clinical development and leadership experience largely focused on Oncology, including the combination of cytokines and check-point inhibitors.
VICE PRESIDENT, BUSINESS DEVELOPMENT
Mr. Smith brings over 12 years of business development leadership experience in the life sciences industry.
VICE PRESIDENT, PROGRAM & ALLIANCE MANAGEMENT
Dr. Schinagl has more than 25 years of program and alliance management experience in the pharmaceutical, biotech, and device industries.
VICE PRESIDENT, PRODUCT ENGINEERING
Mr. Silverman joins OncoSec with over two decades of electroporation device quality and manufacturing experience
Board of Directors
MARGARET R. DALESANDRO, Ph.D.
Dr. Dalesandro brings more than 25 years of drug development experience in the pharmaceutical, biotechnology and diagnostics industries.
ROBERT E. WARD
Mr. Ward is currently the Chief Executive Officer and Chairman of the Board of Eloxx Pharmaceuticals, Inc., roles he has held since December 2017. He was a Director and Chair of the Governance Committee of Akari Therapeutics from October 2016 to August 2018.
HERBERT KIM LYERLY, MD
Dr. Herbert Kim Lyerly is the George Barth Geller Professor of Cancer Research, professor of surgery, immunology and pathology, and director of the surgical sciences applied therapeutics section at Duke University.
Chao Zhou is currently the Executive Deputy Officer of China Grand Pharmaceutical and Healthcare Holdings Limited, a public company listed on the Hong Kong stock exchange.
KEVIN R. SMITH
Kevin R. Smith is currently the Chief Executive Officer of Sirtex Medical US Holdings, Inc. He combines more than 20 years of sales and marketing experience in the medical device industry with the keen instincts of an entrepreneur.
JIM DEMESA, M.D., MBA
Dr. DeMesa has served as a senior executive with several international pharmaceutical and biotech companies in the areas of corporate management, regulatory affairs, and pre-clinical and clinical pharmaceutical and medical device product development.
YUHANG ZHAO, Ph.D., MBA
Dr. Yuhang Zhao, a graduate from Peking University, received her Doctorate in Molecular Biology from Rockefeller University and her MBA in Finance from NYU Stern Business School.
Joon Kim is a highly accomplished attorney and partner in Lee & Ko’s Corporate, International Litigation and Dispute Resolution, and White Collar Crime Practice Groups. Mr. Kim advises clients, both domestic and international, on a broad range of litigation, dispute-resolution and transactional matters.
Scientific Advisory Board
RICHARD HELLER, Ph.D.
Dr. Heller has over 25 years of experience in evaluating effects of electric pulses on biological systems. He is recognized as a pioneer on the use of electrotransfer for drug and gene delivery.
IACOB MATHIESEN, Ph.D.
Dr. Mathiesen has a Ph.D. from University of Oslo, Norway. He was a co-founder of Inovio AS, Norway and inventor on numerous electroporation related patents covering devices and methods for gene based immune therapy.
SOLDANO FERRONE, M.D., Ph.D.
Dr. Ferrone leads a research program focused on the characterization of escape mechanisms deployed by tumor cells to avoid immune-mediated recognition and destruction.
Clinical Advisory Board
ALAIN ALGAZI M.D.
Associate Professor, Department of Medicine (Hematology / Oncology), UCSF Program Leader, UCSF Head and Neck Medical Oncology Melanoma Specialist, UCSH Medical Center
ROBERT H.I. ANDTBACKA, M.D., CM, FACS, FRCSC
Associate Professor, Surgical Oncology Department of Surgery University of Utah, Co-Director Melanoma Program, Co-Director Melanoma Clinical Research Program Huntsman Cancer Institute
AXEL HAUSCHILD, M.D., Ph.D.
Professor of Dermatology, Department of Dermatology, University Hospital Schleswig-Holstein in Kiel, Germany
GEORGINA LONG, BSc, Ph.D., MBBS, FRACP
Conjoint Medical Director Melanoma Institute Australia, Professor of Melanoma Medical Oncology and Translational Research Melanoma Institute Australia, University of Sydney, Royal North Shore Hospital
PAMELA MUNSTER, M.D.
Professor, Department of Medicine (Hematology/Oncology), UCSF; Director, Early Phase Clinical Trials Unit, Co-leader of the Center for BRCA Research, and Leader, Experimental Therapeutics Program, UCSF Helen Diller Family Comprehensive Cancer Center
WALTER J URBA, M.D., Ph.D.
Medical Oncologist; director of cancer research; co-director, Providence Melanoma Programy